Pharmaceuticals Pipeline


Iloprost

Our lead investigative pharmaceutical product is iloprost and it is currently in clinical development. Our aim is to achieve the reduction of moderate to severe lung dysplasia as measured by the LuCED® lung test, and to qualify iloprost as a first-in-class lung cancer chemoprevention treatment. Iloprost, an oral prostacyclin analog, has progressed through an NCI-sponsored Phase 2 clinical trial and achieved a significant reduction in bronchial dysplasia. Iloprost will be developed with the LuCED® lung test as its companion diagnostic. VisionGate is also evaluating iloprost clinical development opportunities for the prevention of lung cancer in high-risk patients and the prevention of lung cancer recurrence in early stage lung cancer patients.

PRESS RELEASE:
Lung Cancer Pioneers Create Lung Cancer Eradication Pact: VisionGate Acquires Exclusive Rights to University of Colorado’s Chemoprevention Drug Iloprost – Partnership Would Combine Company’s Patented Technology that Detects Precancer of the Lungs with Drug Treatment that Prevents Cancer

PHOENIX, Ariz. (January 7, 2016) – VisionGate, Inc., an emerging biotech company in the early lung cancer detection space today announced it has acquired exclusive rights to the University of Colorado’s patent for the use of the drug Iloprost in the prevention of lung cancer, making it one of the first companies to evolve from a diagnostic company to a synergistic diagnostic and therapeutic company.

READ MORE: Complete Press Release


1Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers, Keith et.al., Cancer Prev Res (Phila). 2011 Jun; 4(6): 793–802


This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.


Copyright 2017 - VisionGate, Inc.